Drug support in a complex of rehabilitation measures for patients with post-motor impairment: the role of neurocytoprotectors
https://doi.org/10.21518/2079-701X-2018-9-88-97
Abstract
The article is devoted to medical support of rehabilitation measures for post-stroke motor disorders. The approach to the selection of neurocytoprotectors from the positions of the concept of neuroplasticity and multimodal action is considered. The results of our own observation of the use of citicoline (Ceraxon ®) in the complex program of medical rehabilitation of patients after ischemic stroke are presented. The high efficiency of citicoline application in complex rehabilitation of patients in the early recovery period of ischemic stroke is shown in the form of improving walking function, increasing functional independence, daily activity and quality of life.
Conclusions. The use of modern neurocytoprotectors in a complex of rehabilitation programs is an important and indispensable component for achieving the maximum possible results of rehabilitation aimed at improving the functioning and quality of life of patients.
About the Authors
E. V. Kostenko
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
L. V. Petrova
Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine of Moscow Healthcare Department
Russian Federation
Russian Federation
References
1. Bo Norrvin, Brett Kissela. The global burden of stroke and need for a continuum of care. Neurology, 2013: 5-10.
2. Brainin М. Poststroke spasticity. Treating to the disability. Neurology, 2013: 1-4.
3. Damulin IV, Kononenko EV. Motor impairment after stroke: pathogenetic and therapeutic aspects. Consilium medicum, 2007, 2: 86-91.
4. Khaliullina NR, Rechkalov AV. Locomotor rehabilitation in patients who underwent ischemic stroke. Scientific forum: Medicine, biology and chemistry: collection of articles based on the materials of the 2nd Intern. Scientific-Practical. Conf. 2(2). Moscow: MCNO Publishing, 2016: 58-65.
5. Ivanova GE, Melnikova EV, Shmonin AA, Shamalov NA, Stakhovskaya LV. Drug support of rehabilitation process in patients with acute cerebrovascular disease. Consilium medicum, 2016, 18, 2 (1): 20-24.
6. Gusev EI, Skvortsova VI. Cerebral ischemia. M., 2001: 327 p, p. 6
7. Ivanova GE, Shklovsky VM, Petrova E, et al. The principles of early rehabilitation for stroke patients. Kachestvo Zhizni. Meditsina, 2006, 2: 62-70.
8. Kadykov AS, Chernikova LA, Shakhparonova NV. Rehabilitation of neurological patients. М.: MEDpress-inform, 2008, 560 p.
9. Kamaeva OV, Monro P. Multidisciplinary approach to the management and early rehabilitation of neurological patients: a methodical handbook. Edited by Skoromets AA. SPb. 2003, 20 p.
10. Ferrakhov AZ, Khabirov FA, Ibragimov MF, et al. Complex rehabilitation of patients with ischemic stroke, at the stages hospital - rehabilitation center - polyclinic. Nevrologicheskiy Vestnik, 2012. XLIV (issue 4): 3-8.
11. Adams HP, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, 2007, 38(5): 1655-711.
12. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis, 2008, 25: 457-507.
13. Gusev EI, Skvortsova VI. Neuroprotective therapy of ischemic stroke. Atmosfera, 2002, 1: 3-7.
14. Melnikova EV. Multifactorial neuroprotection in acute and chronic cerebrovascular insufficiency (clinical and experimental research): extended abstract of MD Dissertation. St. Petersburg, 2007. 44 p.
15. Bacigaluppi M, Hermann DM. New targets of neuroprotection in ischemic stroke. Scientific World Journal, 2008, 13(8): 698-712.
16. Chacon MR, Jensen MB, Sattin JA, Zivin JA. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial. Curr Cardiol Rep, 2008, 10(1): 37-42.
17. Donnan GA. A New Road Map for Neuroprotection. The 2007 Feinberg Lecture. Stroke, 2008, 39: 242.
18. Green AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol, 2008, 153(Suppl 1): 325-38.
19. Steiger HJ, Hanggi D. Ischaemic preconditioning of the brain, mechanisms and applications. Acta Neurochir (Wien), 2007, 149(1): 1-10.
20. Young AR, Ali C, Duretete A, Vivien D. Neuroprotection and stroke: time for a compromise. J Neurochem, 2007, 103: 1302-1309.
21. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies – the need for new approaches. Cerebrovasc Dis, 2004, 17(Suppl 1): 153-66.
22. Domashenko MA, Maksimova MYu, Sergeev DV, Piradov MA. Citicoline in treatment of ischemic disorders of cerebral circulation. RMJ, 2013, 30: 1540-1542.
23. Piradov MA, Sergeev DV, Krotenkova MV. The use of ceraxon in the acute period of hemispheric ischemic stroke: clinical and CT-perfusion evaluation. Ann. Klinical. i Experiment. Nevro l., 2012, 3: 31-36.
24. Sergeev DV, Piradov MA. Citicoline in treatment of ischemic stroke: new evidence of effectiveness. RMJ, 2012, 31: 1552-1554.
25. Andersen M, Overgaard K, Meden P et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke, 1999, 30: 1464–71.
26. Alonso de Lecinana M, Gutierrez M, Roda JM et al. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci, 2006, 247: 121–9.
27. Alvarez XA, Laredo M, Corzo D et al. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol, 1997, 19: 201-10.
28. Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol Res, 1996, 18: 570-4.
29. Bolland K, Whitehead J, Cobo E, Secades JJ. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat, 2009, 8: 136-49.
30. Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol, 2009, 31: 171-6.
31. Clark WM, Warach SJ, Pettigrew LC et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology, 1997, 49: 671-8.
32. Clark WM, Williams BJ, Selzer KA et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke, 1999, 30: 2592-97.
33. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology, 2001, 57: 1595-602.
34. Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev, 2004, 9: 17-31.
35. Davalos A, Castillo J, Alvarez-Sabin J et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 2002, 33: 2850-7.
36. Fioravanti M, Yanagi M. Cytidinedi phosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev, 2005, 2: CD000269.
37. Hurtado O, Cаrdenas A, Pradillo JM et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis, 2007, 26: 105-11.
38. Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol, 2009, 5: 33-8.
39. Lozano Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung, 1983, 33: 1073-80.
40. Petkov VD, Kehayov RA, Mosharrof AH et al. Effects of cytidine diphosphate choline on rats with memory deficits. Arzneimittelforschung, 1993, 43: 822-8.
41. Schabitz WR, Weber J, Takano K et al. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci, 1996, 138: 21-5.
42. Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp Neurol, 2000, 161: 733-9.
43. Tazaki Y, Sakai F, Otomo E et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke, 1988, 19: 211-6.
44. Shmonin AA, Prosvirina MS, Simanenkova AV. Endogenous neuroprotection in cerebrovascular diseases. Vestn. Vosstanovitelnoi Meditsiny, 2014, 3: 118-200.
45. Order of the Russian Ministry of Health No. 1740n On Approval of the Standard of Specialized Medical Care for Cerebral Infarction (Registered in the Ministry of Justice of Russia on 05/05/2013, No. 27483) of December 29, 2012. Available at: http://base.garant.ru/70338720/. The link is active as of August 08, 2016.
46. Kostenko EV, Petrova LV. Early rehabilitation period of cerebral stroke: therapeutic potential of cholinergic drugs. Consilium Medicum, 2017, 19 (2.1): 17-24.
47. Kostenko EV, Petrova LV. Neuroplasticity is the basis of modern concept of neurorehabilitation. Selected lectures on medical rehabilitation. Edited by Razumova AN, Turova EA, Korysheva VI. Tambov: Yulis Publishing House LLC, 2016: 40-52.
Review
For citations:
Kostenko EV, Petrova LV. Drug support in a complex of rehabilitation measures for patients with post-motor impairment: the role of neurocytoprotectors. Meditsinskiy sovet = Medical Council. 2018;(9):88-97. (In Russ.) https://doi.org/10.21518/2079-701X-2018-9-88-97
Views:
764
Email this article 